Yes — pyrexia has been reported as a side effect of Lincomycin in FDA adverse-event reports (FAERS) and product labeling. It is among the more frequently reported events for this medication. These are voluntary reports, so they show what's been reported, not how often it happens.
Boxed warning
Warning Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including lincomycin injection and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because lincomycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. diffficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated.
Reported adverse reactions
ADVERSE REACTIONS The following reactions have been reported with the use of lincomycin and are listed by System Organ Class. Frequencies are defined as: commom (≥1% and<10%) uncommon (≥0.1% and <1%), rare (≥0.01% and <0.1%) and not known (cannot be estimated from the available data). Gastrointestinal disorders Common: persistent diarrhea (4.3%), nausea (1.8%), vomiting (1.6%) Rare: stomatitis (0.04%) Not known: glossitis, abdominal discomfort, and pruritus Skin and subcutaneous tissue disorders Uncommon: rash (0.8%), urticaria (0.1%) Rare: pruritus (0.4%) Infections and infestations Uncommon: vaginal infection (0.12%) Not known: pseudomembranous colitis, Clostridium difficile colitis (see WARNINGS ) Blood and lymphatic system disorders Not known: pancytopenia, agranulocytosis, aplastic anemia, leukopenia, neutropenia, thrombocytopenic purpura Immune system disorders Not known: anaphylactic reaction (see WARNINGS ) angioedema, serum sickness Hepatobiliary disorders Not known: jaundice, liver function test abnormal, transaminases increased Renal and urinary disorders Not known: renal impairment, oliguria, proteinuria, azotemia ¹No direct relationship of LINCOCIN to renal damage has been established. Cardiac disorders Not known: cardio-respiratory arrest (see DOSAGE AND ADMINISTRATION) Vascular disorders Not known: hypotension (see DOSAGE AND ADMINISTRATION ), thrombophlebitis² ²Event has been reported with intravenous injection. Ear and labyrinth disorders Not known: vertigo, tinnitus Not known: injection site abscess sterile³, injection site induration³, injection site pain³, injection site irritation³ ³Reported with intramuscular injection.
Warnings
WARNINGS See BOXED WARNING . Clostridioides difficile associated diarrhea Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Lincomycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. Hypersensitivity Severe hypersensitivity reactions, including anaphylactic reactions and severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and erythema multiforme (EM) have been reported in patients receiving Lincomycin Injection, USP therapy. If an anaphylactic reaction or severe skin reaction occurs, Lincomycin Injection, USP should be discontinued and appropriate therapy should be initiated. (See ADVERSE REACTIONS ) Benzyl Alcohol Toxicity in Pediatric Patients (Gasping Syndrome) Lincomycin injection contains benzyl alcohol as a preservative. The preservative benzyl alcohol has been associated with serious adverse events, including the "gasping syndrome", and death in pediatric patients. Although normal therapeutic doses of this product ordinarily deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the "gasping syndrome", the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidneys' capacity to detoxify the chemical. Premature and low-birth weight infants may be more likely to develop toxicity. Inadequate for Use in Meningitis Although lincomycin appears to diffuse into cerebrospinal fluid, concentrations of lincomycin in the CSF may be inadequate for the treatment of meningitis.
Yes — pyrexia has been reported as a side effect of Lincomycin in FDA adverse-event reports (FAERS) and/or its labeling. These are voluntary reports, so they show what's been reported, not how often it happens.
How common is pyrexia with Lincomycin?
pyrexia is among the more frequently reported events for Lincomycin in FAERS. Reporting volume isn't a true incidence rate — check the prescribing information for documented frequencies.
What should I do if I have pyrexia while taking Lincomycin?
Don't stop a prescribed medication on your own. Tell your prescriber or pharmacist — they can tell you whether it's expected, whether it needs attention, and what to do next.
Informational only, drawn from FDA adverse-event reporting (FAERS) and labeling — not medical advice, and not proof a medication caused an effect. Talk to your clinician or pharmacist about any side effect.
Look up another medication
Powered by Eleplan
Tracking a side effect is easier when the whole plan is in one place.
Log symptoms, keep every medication and its history, and prep questions for your next visit — with Ellie, your AI care assistant, on top of it all. Free to start.